K
Kunbo Wang
Researcher at Johns Hopkins University
Publications - 16
Citations - 282
Kunbo Wang is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Medicine & Hazard ratio. The author has an hindex of 4, co-authored 9 publications receiving 57 citations. Previous affiliations of Kunbo Wang include Johns Hopkins University School of Medicine.
Papers
More filters
Journal ArticleDOI
Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19.
Brian T. Garibaldi,Kunbo Wang,Matthew L Robinson,Scott L. Zeger,Karen Bandeen-Roche,Mei Cheng Wang,G. Caleb Alexander,Amita Gupta,Robert C. Bollinger,Yanxun Xu,Yanxun Xu +10 more
TL;DR: In this article, the authors examined whether remdesivir administered with or without corticosteroids for treatment of coronavirus disease 2019 (COVID-19) is associated with more rapid clinical improvement in a racially/ethnically diverse population.
Journal ArticleDOI
Racial and Ethnic Discrepancy in Pulse Oximetry and Delayed Identification of Treatment Eligibility Among Patients With COVID-19.
Ashraf Fawzy,Tianshi David Wu,Kunbo Wang,Matthew L Robinson,Jad Farha,Amanda Bradke,Sherita Hill Golden,Yanxun Xu,Brian T. Garibaldi +8 more
TL;DR: In this article , the authors investigated whether there is differential inaccuracy of pulse oximetry by race or ethnicity among patients with COVID-19 and estimate the association of such inaccuracies with time to recognition of eligibility for oxygen threshold-specific COVID19 therapies.
Journal ArticleDOI
Development of Severe COVID-19 Adaptive Risk Predictor (SCARP), a Calculator to Predict Severe Disease or Death in Hospitalized Patients With COVID-19.
Shannon Wongvibulsin,Brian T. Garibaldi,Annukka A.R. Antar,Jiyang Wen,Mei Cheng Wang,Amita Gupta,Robert C. Bollinger,Yanxun Xu,Kunbo Wang,Joshua Betz,John Muschelli,Karen Bandeen-Roche,Scott L. Zeger,Matthew L Robinson +13 more
TL;DR: The Severe COVID-19 Adaptive Risk Predictor (SCARP) as mentioned in this paper was developed to predict the 1-day and 7-day risks for progression to severe disease or death for any given day during the first 14 days of hospitalization.
Journal ArticleDOI
Tocilizumab for the Treatment of COVID-19 Among Hospitalized Patients: A Matched Retrospective Cohort Analysis
Elisa H. Ignatius,Kunbo Wang,Kunbo Wang,Andrew H. Karaba,Matthew L Robinson,Robin K. Avery,Paul W Blair,Natasha Chida,Tania Jain,Brent G. Petty,Zishan K. Siddiqui,Michael T. Melia,Paul G. Auwaerter,Yanxun Xu,Brian T. Garibaldi +14 more
TL;DR: In this article, marginal structural Cox models via inverse probability treatment weights were applied to estimate the effect of Tocilizumab, an interleukin-6 antagonist, in adjunctive immune-modulating therapy for severe acute respiratory syndrome coronavirus 2 infection.
Journal ArticleDOI
Weight and Body Mass Index Change After Switching to Integrase Inhibitors or Tenofovir Alafenamide Among Women Living with HIV.
Cecile D. Lahiri,Yanxun Xu,Kunbo Wang,Jessica A. Alvarez,Anandi N. Sheth,Jane A. O’Halloran,Amanda Spence,Phyllis C. Tien,Phyllis C. Tien,Deborah R. Gustafson,Joel Milam,Margaret A. Fischl,Deborah Konkle-Parker,Adaora A. Adimora,Anjali Sharma,Kathleen M. Weber,Igho Ofotokun,Leah H. Rubin,Leah H. Rubin +18 more
TL;DR: Significant, albeit small-to-medium, increases in weight and BMI occurred among non-obese women who switched to INSTIs and/or TAF over short follow-up, and identifying women at highest risk of ART-associated weight gain is imperative.